Research Paper Volume 10, Issue 10 pp 2755—2771
Pretreatment TACC3 expression in locally advanced rectal cancer decreases the response to neoadjuvant chemoradiotherapy
Figure 4. Effects of clinical variables on 5-year overall and disease-free survival rates. (A-D) Five-year overall survival rates among the 152 rectal cancer patients, taking into account TACC3 expression, the presence of tumor deposits, the CEA level, and adjuvant chemotherapy cycles. (E-I) Five-year disease-free survival rates among the 152 rectal cancer patients, taking into account TACC3 expression, the presence of tumor deposits, the CA19-9 level, the number of adjuvant chemotherapy cycles, and tumor differentiation.